Navigation Links
Cepheid Reports Fourth Quarter And Full Year 2012 Results
Date:1/24/2013

us risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our ability to successfully complete and bring on line additional manufacturing lines; our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program and the level of sales through that program; other unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

'/>"/>
SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Announces Executive Vice President Emerging Markets
3. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
4. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
5. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
8. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
9. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
10. Luminex Corporation Reports First Quarter 2012 Results
11. Hospira Reports First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 The Cadence Fitness & ... Center by the Medical Fitness Association, a non-profit organization ... their full potential. The Cadence Fitness & Health Center ... suburbs and second in the Chicagoland area. ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Ortho-McNeil Pharmaceutical LLC, a subsidiary of Johnson & Johnson, pled guilty ... misdemeanor violation of the Food, Drug & Cosmetic Act for illegally promoting its ... company was also sentenced at today,s hearing. , ... U.S. Attorney Carmen M. Ortiz and Tony West ...
... , May 21 The SCOOTER Store is supporting the ... San Antonio, believing that teaching ethics and humanitarian values to future doctors ... , , ... SCOOTER Store is to create an opportunity for every American senior to ...
Cached Medicine Technology:Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million 2Ortho-McNeil Pharmaceutical, LLC Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million 3The SCOOTER Store Invests in Ethics Training for Future Doctors 2The SCOOTER Store Invests in Ethics Training for Future Doctors 3
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
(Date:4/17/2014)... An international team led by researchers at UC ... which plays a key role in cell division, also ... is the first time the complex has been shown ... cyclin B1/Cdk1 an excellent target to control cellular energy ... research was published online today in the journal ...
(Date:4/17/2014)... ribbon representing a disease. A pink ribbon is well known ... think of with lung cancer?, Although white has been identified ... black may be the only one they think fits., A ... smokers between the ages of 51 to 79 years old, ... these patients, the emotional toll it can have and how ...
(Date:4/17/2014)... has found that India,s shocking rates of suicide are ... are clinging to tiny smallholdings less than one ... as cotton and coffee, that are highly susceptible to ... of previous case studies that point to a crisis ... ,liberalisation, of the nation,s economy during the 90s. Researchers ...
(Date:4/17/2014)... status as the leading weapon against the deadly disease ... new research indicating it simply needs to be administered ... the cheap anti-malarial drug chloroquine in treating and preventing ... than half a million people each year around the ... resistance to chloroquine, but research carried out at the ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Scientists find new way to fight malaria drug resistance 2
... drugs used to treat anemia may undermine breast cancer ... cancer-promoting HER2 protein, researchers from The University of Texas ... edition of Cancer Cell . "Our research ... same time, Herceptin was less effective," said study senior ...
... MONDAY, Nov. 15 (HealthDay News) -- In Australia, where universal ... much more prevalent among poor citizens than it is among ... researchers say that differences in risk do exist between the ... heart disease is typically thought of as more prevalent in ...
... 15 (HealthDay News) -- Warfarin patients who use herbal ... with the blood thinner may make it ineffective and ... based on a survey of 100 patients currently taking ... the herbal supplements with high-risk medicines, exposing themselves to ...
... find some way to disarm p53, also known as "guardian ... cells from dividing. "The critical importance of the protective function ... employed by cancer cells to subvert p53 activity, such as ... study author Dr. Loren D. Walensky from Harvard Medical School. ...
... At-TRIB(1)-uting a gene a new function in the liver ... human chromosome 8 have recently been linked to fat (lipid) ... atherosclerosis (a disease of the major arterial blood vessels that ... only currently described gene in this region of chromosome 8 ...
... University of Liverpool has launched an i-phone application, ... with instant and easy access to information about ... ( www.hiv-druginteractions.org ), HIV iChart is a tool ... immediate access to information on potential drug interactions ...
Cached Medicine News:Health News:Erythropoietin counteracts breast cancer treatment with herceptin 2Health News:Erythropoietin counteracts breast cancer treatment with herceptin 3Health News:Universal Health Care May Lessen Income's Impact on Heart Disease 2Health News:Warfarin Patients Often Unaware of Risks from Herbs, Supplement Use 2Health News:Targeted therapy reactivates 'guardian of the genome' in resistant cancer 2Health News:JCI online early table of contents: Nov. 15, 2010 2Health News:JCI online early table of contents: Nov. 15, 2010 3Health News:JCI online early table of contents: Nov. 15, 2010 4Health News:JCI online early table of contents: Nov. 15, 2010 5Health News:JCI online early table of contents: Nov. 15, 2010 6Health News:University launches iPhone app to access HIV drug expertise 2
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum Controller V-800 and ... levels from Model V-500 is ... handle most vacuum applications. Applications ... rotary evaporators Laboratory vacuum source for ...
Medicine Products: